PRNewsWire
21 May 2026, 21:05 UTC · 16w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Whitehawk Therapeutics entered into an option agreement with Hangzhou DAC for the use of CPT113 linker-payload in up to five new ADC programs. — Pipeline expansion via new development options increases the long-term growth potential and asset diversification of a clinical-stage biotech.
+0.40Phase 1 dose-escalation trials for HWK-007 and HWK-016 are currently enrolling, with data expected in the first half of 2027. — Active clinical enrollment is a key milestone for biotech valuation, though the long timeframe until data delivery limits immediate impact.
+0.30External validation of the CPT113 technology is provided by Hangzhou DAC's DXC006 data at ASCO and Johnson & Johnson's preclinical findings for JNJ-95437446. — Third-party clinical and preclinical success with the same core technology reduces the perceived technical risk of Whitehawk's platform.
+0.20Continue reading
5 related stories
Top 1 mover · tap to explore
Whitehawk anticipates submitting Investigational New Drug (IND) applications for multiple new programs over the next 12-24 months. — Provides a roadmap for near-term catalysts, though IND filings are regulatory steps rather than proof of efficacy.
+0.10Which stocks this story touches
The company expanded its ADC pipeline via a new option agreement and is advancing multiple clinical-stage programs.
Clinical data for its DXC006 program reinforces the validity of the linker-payload technology used by the company.
Reported positive preclinical findings for an ADC program utilizing CPT113.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
4h ago
